Skip to content
Veeda Clinical Research logo
Pre-IPOPublic Limited

Veeda Clinical Research Unlisted Share Price

Veeda Clinical Research Limited (CRO)

Healthcare·Pharmaceuticals

CIN
U73100GJ2004PLC044023
ISIN
INE01HQ01026
Incorporated
23 Apr 2004
Registered state
Gujarat

Key valuation

Market cap
₹2,990 Cr
P/E
—
Debt / equity
—
Shares outstanding
6,98,59,813

Indicative price

₹428prev ₹428

1M

0.00%

6M

-4.46%

1Yr

-6.96%

Max

-28.67%

Updated 17 Nov 2026, 08:10

Prices shown are indicative, dealer-quoted and updated periodically — they are not exchange-traded prices and may differ from the price at which a transaction is finally executed.

Price history

Dated dealer-quote averages, plotted on a true time scale. There is no continuous trading behind these numbers.

-6.96%since 17 Nov 2025High ₹460Low ₹428321 dated snapshots

About Veeda Clinical Research

Veeda Clinical Research Limited is a contract research organisation (CRO) based in Ahmedabad and founded in 2004. It runs clinical studies for pharmaceutical and biotech companies around the world.

Its services include bioavailability and bioequivalence studies, phase I to IV clinical trials, clinical data management, pharmacovigilance and biostatistics, carried out to international regulatory standards. Binoy Gardi is the CEO and Managing Director.

Veeda reported revenue of ₹715 crore and a net loss of ₹7 crore in FY2026, much smaller than the ₹67 crore loss in FY2025.

Key highlights

  • Incorporated in 2004

Financial snapshot

FY2026

Revenue FY2026
₹715.49 Cr
EBITDA
₹226.30 Cr
PAT
₹-6.55 Cr
Net worth
—
Total debt
₹421.40 Cr
Cash & equivalents
—
Operating cash flow
₹238.72 Cr
EPS
₹-0.94

Management & board

  • NJ

    Nitin Jagannath Deshmukh

    Director

    Since 2021
  • BH

    Binoy Hasmukh Gardi

    CEO, Additional Director, Managing Director

    Since 2026
  • KV

    Kiran Vithaldas Marthak

    Director

    Since 2020
  • AB

    Apurva Bhupendra Shah

    Additional Director

    Since 2026
  • VC

    Vivek Chhachhi

    Nominee Director

    Since 2018
  • VP

    Vinayak Prabhakar Shenvi

    Nominee Director

    Since 2025
  • RB

    Rakesh Bhartia

    Director

    Since 2021
  • SN

    Shankarappa Nagaraja Vinaya Babu

    Director

    Since 2021
  • TA

    Tanushree Akshay Agarwal

    Nominee Director

    Since 2024
  • NA

    Nirmal Atmaram Bhatia

    CFO, Company Secretary

    Since 2021
  • JF

    Jeanne Frances Taylor Hecht

    Director

    Since 2021
  • DP

    David Paul Kenny

    Director

    Since 2024
  • GK

    Georgios Kouvatseas .

    Nominee Director

    Since 2025

Reported financials · FY2022–FY2026

Figures in ₹ crore unless stated.

Revenue CAGR 25.5%
ParticularsFY2022FY2023FY2024FY2025FY2026YoYCAGR
Profit & loss
Revenue from operationsYoY +17.4%CAGR +25.5%288410389610715+17.4%+25.5%
Other incomeYoY +48.2%CAGR +34.9%511191117+48.2%+34.9%
Total expensesYoY +5.6%CAGR +29.0%262358405687725+5.6%+29.0%
EBITDAYoY +65.9%CAGR +35.8%6711471136226+65.9%+35.8%
Depreciation & amortisationYoY +6.2%CAGR +57.7%253853148157+6.2%+57.7%
EBITYoY —CAGR +14.0%417618-1169—+14.0%
Finance costYoY +14.2%CAGR +59.4%1014155462+14.2%+59.4%
Profit before taxYoY —CAGR -30.5%32623-667—-30.5%
Tax expenseYoY +969.2%CAGR -2.7%16174114+969.2%-2.7%
Profit after tax5142-0-67-7——
Earnings per share₹7.23₹6.07₹-0.06₹-9.56₹-0.94——
Balance sheet
Net worthYoY -19.1%CAGR +25.4%4374631,065862—-19.1%+25.4%
Total debtYoY +3.8%CAGR +62.7%6049262406421+3.8%+62.7%
Current liabilitiesYoY +2.3%CAGR +30.8%151181512433443+2.3%+30.8%
Current assetsYoY +25.9%CAGR +16.8%312294557462582+25.9%+16.8%
Total assetsYoY +9.7%CAGR +31.8%6787352,0401,8632,044+9.7%+31.8%
Cash flow
Operating activitiesYoY +616.9%CAGR +60.6%361065933239+616.9%+60.6%
Investing activities-154-126-447-149-56——
Financing activitiesYoY -215.9%CAGR —163-140091-106-215.9%—
Free cash flowYoY +3721.6%CAGR +132.4%730-246210+3721.6%+132.4%
Net change in cashYoY —CAGR +14.4%45-2212-2577—+14.4%

YoY compares the latest year with the one before it. CAGR runs from the oldest reported year to the latest. A dash means the year is missing, or the starting figure is zero or negative, so a percentage would mislead.

Margins, returns, liquidity, leverage and every other ratio from these figures: see Ratios

Revenue, EBITDA and PAT

₹ crore. A year with no reported figure is left out rather than drawn as zero.

-67129324520715FY2022 · Revenue: 288FY2022 · EBITDA: 67FY2022 · PAT: 51FY2022FY2023 · Revenue: 410FY2023 · EBITDA: 114FY2023 · PAT: 42FY2023FY2024 · Revenue: 389FY2024 · EBITDA: 71FY2024 · PAT: -0FY2024FY2025 · Revenue: 610FY2025 · EBITDA: 136FY2025 · PAT: -67FY2025FY2026 · Revenue: 715FY2026 · EBITDA: 226FY2026 · PAT: -7FY2026
-67129324520715FY2022 · Revenue: 288FY2022 · EBITDA: 67FY2022 · PAT: 51FY2022FY2023 · Revenue: 410FY2023 · EBITDA: 114FY2023 · PAT: 42FY2023FY2024 · Revenue: 389FY2024 · EBITDA: 71FY2024 · PAT: -0FY2024FY2025 · Revenue: 610FY2025 · EBITDA: 136FY2025 · PAT: -67FY2025FY2026 · Revenue: 715FY2026 · EBITDA: 226FY2026 · PAT: -7FY2026
  • Revenue
  • EBITDA
  • PAT

Every ratio here is worked out from the reported figures in the Financials tab, and valuation multiples from the indicative price in the header. Nothing is a stored value. A ratio the filings cannot support (a line not reported, or a zero or negative base) is left out or shown as —, never as a misleading number. Balance-sheet ratios use year-end figures.

Valuation multiples

What the indicative price pays for the latest year's earnings, book and cash. On FY2026 figures and the ₹428 indicative price.

Market cap
₹2,990 Cr
Enterprise value
₹3,411 Cr
Price / sales (P/S)
4.18x
Price / operating cash flow
12.53x
EV / EBITDA
15.07x
EV / EBIT
49.16x
EV / sales
4.77x
Earnings yield
-0.2%
Free cash flow yield
7.0%
How these are worked out
Market cap
Indicative price × shares outstanding
Enterprise value
Market cap + debt − cash
Price / sales (P/S)
Market cap ÷ revenue from operations
Price / operating cash flow
Market cap ÷ cash from operating activities
EV / EBITDA
Enterprise value ÷ EBITDA
EV / EBIT
Enterprise value ÷ (EBITDA − depreciation)
EV / sales
Enterprise value ÷ revenue from operations
Earnings yield
PAT ÷ market cap
Free cash flow yield
(Operating cash flow − capex) ÷ market cap

Shareholding pattern

As at 31 Mar 2026

Largest holder: Basil Private Limited 31.85%

31.9%18.1%50.1%

IPO / listing status

Pre-IPONot yet announced

The company has not announced IPO details such as a DRHP filing, an expected window or its bankers. This section will update once it does.

Research & news

Information currently unavailable

Nothing has been published on Veeda Clinical Research yet. Research, news and articles tagged with it will appear here when they are.

Browse all research

Documents

Private documents are shown locked and are released to verified clients on request.

DocumentTypeFY / dateAccess
Annual Report FY 2025-26Annual report · FY 2025-26 · 12.7 MB12.7 MBAnnual reportFY 2025-26ViewDownload
Annual Report FY 2024-25Annual report · FY 2024-25 · 2.8 MB2.8 MBAnnual reportFY 2024-25ViewDownload
Annual Report FY 2023-24Annual report · FY 2023-24 · 7.8 MB7.8 MBAnnual reportFY 2023-24ViewDownload

Veeda Clinical Research unlisted shares: FAQs

What is the Veeda Clinical Research unlisted share price today?

The indicative price of Veeda Clinical Research Limited (CRO) shares is ₹428 per share, as of 17 Nov 2026. Unlisted shares have no exchange price: this figure reflects recent off-market deals and can differ from the price on a particular trade. The price history on this page shows how it has moved.

How can I buy Veeda Clinical Research unlisted shares?

Raise a buy enquiry on this page with the number of shares you want. Our desk confirms availability and the price, you pay from a bank account in your own name, and the shares are transferred to your demat account. You need a PAN and a demat account with any depository participant.

How can I sell Veeda Clinical Research shares?

Raise a sell enquiry with the number of shares you hold in demat. Once the price is agreed, you transfer the shares from your demat account and the money is paid to a bank account in your name.

Is Veeda Clinical Research planning an IPO?

Veeda Clinical Research Limited (CRO) is currently at the "Pre-IPO" stage. No IPO date has been announced. A listing depends on the company and on regulatory approval.

What are Veeda Clinical Research's revenue and profit?

In FY26, Veeda Clinical Research Limited (CRO) reported revenue of ₹715 Cr and a loss of ₹7 Cr. The Financials section has the full statements for every year we hold.

Is it legal to buy unlisted shares in India?

Yes. Shares of unlisted public companies can be bought and sold off-market and transferred between demat accounts. They carry more risk than listed shares: prices are not set on an exchange, it can take time to find a buyer, and a listing is never guaranteed.

Is there a lock-in on Veeda Clinical Research shares after the IPO?

SEBI rules lock in shares held before an IPO for a period after listing, currently six months from allotment for most investors in a mainboard IPO. Shares bought now in the unlisted market would usually be covered by this lock-in.

How are gains on Veeda Clinical Research unlisted shares taxed?

Gains on unlisted shares held for more than 24 months are long-term capital gains; held for less, they are short-term and taxed at your slab rate. Check the current rates with a tax adviser before you sell.